These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 16736564)

  • 21. Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials.
    Blanc FX; Havlir DV; Onyebujoh PC; Thim S; Goldfeld AE; Delfraissy JF
    J Infect Dis; 2007 Aug; 196 Suppl 1():S46-51. PubMed ID: 17624825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New drugs for tuberculosis: current status and future prospects.
    O'Brien RJ; Spigelman M
    Clin Chest Med; 2005 Jun; 26(2):327-40, vii. PubMed ID: 15837114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Managing TB in the 21st century: existing and novel drug therapies.
    Guy ES; Mallampalli A
    Ther Adv Respir Dis; 2008 Dec; 2(6):401-8. PubMed ID: 19124385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pediatric urinary tract infections: the role of fluoroquinolones.
    Koyle MA; Barqawi A; Wild J; Passamaneck M; Furness PD
    Pediatr Infect Dis J; 2003 Dec; 22(12):1133-7. PubMed ID: 14688587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment.
    Bock NN; Sterling TR; Hamilton CD; Pachucki C; Wang YC; Conwell DS; Mosher A; Samuels M; Vernon A;
    Am J Respir Crit Care Med; 2002 Jun; 165(11):1526-30. PubMed ID: 12045127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SCV-07 (SciClone Pharmaceuticals/Verta).
    Aspinall RJ; Pockros PJ
    Curr Opin Investig Drugs; 2006 Feb; 7(2):180-5. PubMed ID: 16499289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New approaches to the treatment of latent tuberculosis.
    Sterling TR
    Semin Respir Crit Care Med; 2008 Oct; 29(5):532-41. PubMed ID: 18810686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Key issues in the clinical development and implementation of TB vaccines in South Africa.
    Rustomjee R; Mcleod R; Hanekom W; Steel G; Mahomed H; Hawkridge A; Welte A; Sinanovic E; Loots G; Grobler A; Mvusi L; Gray G; Hesseling A; Ginsberg A; Lienhardt C; Shea J; Tong X; Lockhart S; Churchyard GJ
    Tuberculosis (Edinb); 2012 Sep; 92(5):359-64. PubMed ID: 22698868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rifapentine--a long-acting rifamycin for tuberculosis.
    Med Lett Drugs Ther; 1999 Feb; 41(1047):21-2. PubMed ID: 10076594
    [No Abstract]   [Full Text] [Related]  

  • 31. [Anti-tuberculosis chemotherapy].
    Wada M
    Kekkaku; 2007 Oct; 82(10):771-81. PubMed ID: 18018601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimum time to start antiretroviral therapy in patients with HIV-associated tuberculosis: before or after tuberculosis diagnosis?
    Kerkhoff AD; Wood R; Lawn SD
    AIDS; 2011 Apr; 25(7):1003-6. PubMed ID: 21346513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Balofloxacin Choongwae.
    Alksne L
    Curr Opin Investig Drugs; 2003 Feb; 4(2):224-9. PubMed ID: 12669387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials.
    Bennett CL; George SL; Vose JM; Nemunaitis JJ; Armitage JL; Armitage JO; Gorin NC; Gulati SC
    Stem Cells; 1995 Jul; 13(4):414-20. PubMed ID: 7549900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quinolones for the treatment and prophylaxis of tuberculosis.
    Kaplan JA; Krieff DM
    Ann Pharmacother; 1996 Sep; 30(9):1020-2. PubMed ID: 8876865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paclitaxel activity, dose, and schedule: data from phase III trials in metastatic breast cancer.
    Di Leo A; Piccart MJ
    Semin Oncol; 1999 Jun; 26(3 Suppl 8):27-32. PubMed ID: 10403471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-course instead of long-course chemotherapy for smear-negative patients in sub-Saharan Africa.
    van Gorkom J; van Cleeff M; Becx-Bleumink M; Veen J
    Int J Tuberc Lung Dis; 2001 Jan; 5(1):4-11. PubMed ID: 11263514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New tuberculosis therapeutics: a growing pipeline.
    Spigelman MK
    J Infect Dis; 2007 Aug; 196 Suppl 1():S28-34. PubMed ID: 17624823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis.
    Ena J; Valls V
    Clin Infect Dis; 2005 Mar; 40(5):670-6. PubMed ID: 15714411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new vision for clinical trials in Africa.
    The
    PLoS Med; 2004 Dec; 1(3):e71. PubMed ID: 15630472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.